Deutschland kommt bei der Bekämpfung von Infektionskrankheiten und antimikrobieller Resistenzen eine zentrale Rolle zu. Als Hochleistungsmedizinland kann Deutschland Innovationsmotor im Kampf gegen Infektionen sein. Mit der Deutschen Antibiotika-Resistenzstrategie DART2020 und massiver Unterstützung europäischer Initiativen wie der Global Antibiotic Research and Development Partnership hat Deutschland diesen Kampf in den vergangenen Jahren vorangetrieben. Trotz einzelner Erfolge dürfen die Anstrengungen nicht nachlassen.
Leibniz-IPHT is a strong research partner: Cooperations on the national and international level play a major role in Leibniz-IPHT's research. In the region, Leibniz-IPHT collaborates closely with the University of Jena and the University of Applied Sciences Jena. Within the non-academic institutions in Jena, Leibniz-IPHT takes on a joint role between photonics and the life sciences. In regional networks such as "optonet" and "medways" Leibniz-IPHT is a sought-after partner for industry.
Leibniz-IPHT currently participates as a research partner in more than 120 national joint research projects. In the biophotonics research focus supported by the Federal Ministry of Education and Research (BMBF), Leibniz-IPHT coordinates a program for the development of optical solutions to biological and medical problems.
Leibniz-IPHT has taken on a coordinator role in several projects, including the Leibniz research alliance for healthcare technologies and the "Infectognostics Research Campus Jena" as well as the European Network of Excellence "Photonics4Life".
Leibniz-IPHT currently maintains collaborative efforts with partner from 45 countries, The institute is a founding member of the international network "Biophotonics4Life" and is active in distinguished scientific organizations.
INFECTOGNOSTICS RESEARCH CAMPUS JENA: PUBLIC-PRIVATE PARTNERSHIP FOR INNOVATIONS
The InfectoGnostics research campus is a public-private partnership developing new methods in infection diagnostics. In a triad of technology, application and production, more than 30 partners from science, medicine and industry are developing marketable solutions for rapid and cost-effective point-of-care testing of infections in human medicine, testing systems for animal diseases and for pathogen detection in food. Within the joint project "Pneumonia in Immunosuppression" seven public and private partners aim at developing a reliable, rapid and non-invasive diagnostic tool for pneumonia pathogens and their resistances. The InfectoGnostics research campus is one of nine funded initiatives "Research campus – Public-private Partnership for Innovation" of the Federal Ministry of Education and Research (BMBF).
LEIBNIZ RESEARCH ALLIANCE HEALTH TECHNOLOGIES: PRECISE TECHNOLOGICAL SOLUTIONS FOR URGING MEDICAL QUESTIONS
The Leibniz Research Alliance unites competences from different scientific areas: starting from photonics and medicine to microelectronics and material research, to economic research and applied mathematics. Alliance carefully develops innovative procedures that aid early disease detection, better control the effects of therapy and can easily be adapted to individual patients. These procedures improve treatment methods while minimizing their negative impact on patients. Telemedical and improved imaging examination methods, as well as the development of rapid testing designed for mobile use, also play an important role. Medical professionals, scientists and engineers work together intensively to ensure that the technical solutions adequately address the medical problems. Social scientists investigate questions of marketability and how society will respond to newly developed products.
www.leibniz-healthtech.de (content only available in German)
RESEARCH AND EDUCATION IN THE FIELD OF OPTICS AND PHOTONICS
The Abbe Center of Photonics (ACP) is the academic center of scientific activities in the fields of optics and photonics at the Friedrich-Schiller-Universität (FSU) Jena. Research on fundamental and applied topics is conducted in cooperation with the Fraunhofer Institute Jena, the Helmholtz Institute Jena and the Leibniz Institute of Photonic Technology. Its main mission is to promote interdisciplinary research and education, jointly performed by scientists from different subject areas, spanning physics, material sciences, chemistry, biology and medicine.
ACP follows the vision to be one of the leading European centers for research and education in optics and photonics as well as in the development and transfer of optical technologies until 2020. To this end, the ACP fosters and sustains strong links with local industry partners as well as with the international scientific community.
The “Jena School for Microbial Communication (JSMC)” at the Friedrich Schiller University of Jena is not only an Excellence Graduate School, but also a lively network of scientists from a broad variety of natural & life sciences institutes and an umbrella organization for three Research Training Groups in Jena. The JSMC was first awarded funding within the German Excellence Initiative in 2007. In June 2012 the Excellence Status of the JSMC was confirmed and funding for an additional five years was granted to the Graduate School.
Today, JSMC hosts a total of about 150 doctoral researchers. Their research projects are situated at the numerous institutes that make up the JSMC network, including institutes and clinics at the Friedrich Schiller University Jena as well as non-university research institutions.
JENA BIOPHOTONICS AND IMAGING LABORATORY
The DFG-funded Core Facility Jena Biophotonic and Imaging Laboratory (JBIL) combines spectroscopic and spectrometric techniques and devices present at different facilities in Jena. It is a user-open platform gives researchers in life science and medical applications unique access to method-comprehensive, multi-modal imaging techniques. The JBIL aims at enhancing the collaboration and communication between scientists using spectroscopic and spectrometric techniques and improving the utilisation of the available resources in Jena.
The JBIL is a joint initiative of the Leibniz Institute of Photonic Technology (IPHT), the Jena University Hospital (JUH), in particular the Center for Sepsis Control and Care (CSCC), and the Friedrich Schiller University (FSU) Jena. The JUH is contributing to the JBIL e.g. with the Core Unit Biophotonics of the CSCC.
PHOTONICS IN THE LIFE SCIENCES - LIGHT FOR HEALTH
Using state-of-the-art optical methods, biophotonic research traces the processes of life in order to understand wide-spread disease in their origins, recognize disease symptoms in an early stage and to develop highly-efficient methods for therapy of diseases. On the long run it is hoped, that first warning signs of the human body can be detected in such an early stage, that the outbreak of a disease could be prevented at all. Since 2002, the Federal Ministry for Education and Research (BMBF) supports the scientific field that is highly-relevant to society and economy with a research initiative.
HEMOSPEC – EUROPEAN PARTNERS JOINING FORCES FOR HEALTH
Within the EU-supported research project HemoSpec, a multidisciplinary team of researchers, clinicians and engineers from six European countries has joined forces to develop an innovative device for early, fast and reliable medical diagnosis of infectious diseases and sepsis using only minimal amounts of patient's blood.
Driven by the demands of clinical partners, HemoSpec partners combine three key enabling technologies for precise blood examination. One common user interface, common data storage and analysis software will make the dense information from HemoSpec available to the clinical enduser in a single working step.
Raman4Clinics is an EU-funded networking project in the frame of the European Cooperation in Science and Technology Action (COST-Action). It pools European expertise to step forward in the field of novel, label-free and rapid technologies based on a wide variety of Raman spectroscopies for the clinical diagnostics of body fluids, bacteria, cells and tissues. The Action creates a platform for scientific communication, exchange, collaboration and for new research activities, combining the partners’ expertise in technology, component, system and methodology development and medical application. As a result, novel technology portfolios for clinical diagnostics will emerge to the benefit of patients as well as to the economy.